The Role of the Incretin Hormones GIP and GLP-1 in the Pathogenesis of Type 2 Diabetes

被引：0

作者：

Meier, J. J. ^{[1
]}

机构：

[1] Klinikum Ruhr Univ Bochum, St Josef Hosp, Med Klin 1, D-44791 Bochum, Germany

来源：

DIABETOLOGIE UND STOFFWECHSEL | 2009年 / 4卷 / 05期

关键词：

GASTRIC-INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE-1; DEPENDENT INSULINOTROPIC POLYPEPTIDE; 1ST-DEGREE RELATIVES; ORAL GLUCOSE; RECEPTOR EXPRESSION; 7-36; AMIDE; SECRETION; PLASMA; HYPERGLYCEMIA;

D O I：

10.1055/s-0029-1224610

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The incretin effect, i.e. the postprandial augmentation of insulin secretion by gastrointestinal hormones, mediates similar to 50-70% of the meal-related increments in insulin secretion in healthy individuals. In contrast, the incretin effect is almost completely absent in patients with type 2 diabetes. The impaired incretin effect in type 2 diabetes has been mainly attributed to the reduced insulinotropic activity of GIP, whereas the actions of GLP-1 are largely preserved. Furthermore, a diminished secretion of GLP-1 has been suggested to contribute to the impaired incretin effect in type 2 diabetes, but this finding has not been confirmed in the majority of studies. This article aims to compare the secretion and action of the incretins GIP and GLP-1 between patients with type 2 diabetes and healthy individuals. In addition, the importance of alterations in the entero-insular axis for the pathogenesis of type 2 diabetes will be discussed.

引用

页码：295 / 300

页数：6

共 50 条

[21] The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility
Edholm, T.
Cejvan, K.
Abdel-Halim, S. M.
Efendic, S.
Schmidt, P. T.
Hellstrom, P. M.
NEUROGASTROENTEROLOGY AND MOTILITY, 2009, 21 (03): : 313 - 321
[22] The incretin hormones GIP and GLP-1 in healthy volunteers: Effects on gastric emptying rate and insulin response
Edholm, T
Gryback, P
Lundberg, S
Schmidt, PT
Jacobsson, H
Hellstrom, PM
GASTROENTEROLOGY, 2005, 128 (04) : A608 - A608
[23] Circulating concentrations and prognostic value of incretin hormones GLP-1 and GIP-1 in patients with heart failure
Fernandez Villa, N. Noelia
Pascual-Garcia, A.
Riquelme-Perez, A.
Lax-Perez, A.
Asensio-Lopez, M. C.
Ruiz-Ballester, M.
Ramon-Martinez, A.
Blanco-Pacheco, J. E.
Garcia-Garcia, A. M.
Piqueras-Sanchez, C.
Moreno-Fernandez, J.
Pujante-Martinez, A.
Garrido-Bravo, I. P.
Pastor-Perez, F. J.
Pascual-Figal, D. A.
EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 180 - 181
[24] Gastro-intestinal hormones GIP and GLP-1
Kieffer, TJ
ANNALES D ENDOCRINOLOGIE, 2004, 65 (01) : 13 - 21
[25] Role of Chylomicron Formation and Secretion in the Release of Diabetic Hormones GLP-1 and GIP
Lu, Wendell J.
Yang, Qing
D'Alessio, David
Tso, Patrick
FASEB JOURNAL, 2008, 22
[26] GLP-1 and GIP contribute nearly equally to the incretin effect in humans
Vilsboll, T
Krarup, T
Madsbad, S
Holst, J
DIABETES, 2003, 52 : A325 - A325
[27] GIP and GLP-1 receptor agonism in the therapy of type 2 diabetes with a focus on tirzepatide
Nauck, Michael A.
Blueher, Matthias
Meyhoefer, Sebastian M.
Heitmann, Elke
Goergens, Sven W.
DIABETOLOGIE UND STOFFWECHSEL, 2023, 18 (06) : 475 - 487
[28] Downregulation of GLP-1 and GIP receptor expression by hyperglycemia - Possible contribution to impaired incretin effects in diabetes
Xu, Gang
Kaneto, Hideaki
Laybutt, D. Ross
Duvivier-Kali, Valerie F.
Trivedi, Nitin
Suzuma, Kiyoshi
King, George L.
Weir, Gordon C.
Bonner-Weir, Susan
DIABETES, 2007, 56 (06) : 1551 - 1558
[29] Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes
Vale, Catarina
Lourenco, Ines Mariana
Jordan, Gabriela
Golovaty, Ilya
Torres, Hugo
Moin, Tannaz
Buysschaert, Martin
Neves, Joao Sergio
Bergman, Michael
DIABETES OBESITY & METABOLISM, 2024,
[30] GLP-1 for type 2 diabetes
Ahren, Bo
EXPERIMENTAL CELL RESEARCH, 2011, 317 (09) : 1239 - 1245

← 1 2 3 4 5 →